Generic Name and Formulations:
Vandetanib 100mg, 300mg, tabs.
Sanofi Genzyme Company
Indications for CAPRELSA:
Symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
Do not crush tabs. May disperse tabs in 2oz noncarbonated water for oral or NGT administration; avoid contact of dispersion with skin, mucous membranes. 300mg once daily. Renal impairment (CrCl<50mL/min): initially 200mg once daily. Dose adjustments for adverse reactions: see full labeling. Do not take a missed dose within 12hrs of the next dose.
Congenital long QT syndrome.
QT prolongation, Torsades de pointes, and sudden death.
Hypocalcemia, hypokalemia, hypomagnesemia, QTcF interval >450msec, history of Torsades de pointes, bradyarrhythmias, uncompensated heart failure, recent hemoptysis: not recommended. Ventricular arrhythmias. Recent MI. Monitor electrolytes (esp. K+, Ca++, Mg++), TSH, and ECG for QT prolongation at baseline, 2–4 weeks and 8–12 weeks after starting, then every 3 months, and after dose reductions or dose interruptions >2 weeks; reduce dose as needed. Correct electrolyte disturbances before starting. Maintain serum K+ at least 4mEq/mL. Hepatic impairment (Child-Pugh B or C): not recommended. Interrupt therapy and follow-up if acute or worsening pulmonary symptoms, QTcF >500msec, or CTCAE Grade ≥3 toxicity occurs. Monitor for heart failure; consider discontinuing if occurs. Discontinue if confirmed interstitial lung disease, severe ischemic cerebrovascular event, hemorrhage, uncontrolled hypertension, or posterior leukoencephalopathy symptoms (RPLS) occur. Avoid sun, UV light. Embryo-fetal toxicity. Females of reproductive potential should use effective contraception during and for 4 months after the final dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for 4 months after the final dose).
Avoid strong CYP3A4 inducers (eg, rifampicin, St. John's Wort). Avoid other drugs that can prolong QT interval (eg, amiodarone, disopyramide, procainamide, sotalol, dofetilide, chloroquine, clarithromycin, dolasetron, granisetron, haloperidol, pimozide, methadone, moxifloxacin). Potentiates OCT2 transporters (eg, metformin), digoxin; monitor.
Diarrhea/colitis (suspend if severe), rash, acneiform dermatitis, nausea, hypertension, headache, upper respiratory tract infections, decreased appetite, abdominal pain, hypocalcemia, hypoglycemia, increased ALT; QT prolongation, Torsades de pointes, sudden death, severe skin reactions (eg, toxic epidermal necrolysis, Stevens-Johnson syndrome; permanently discontinue if occurs), photosensitivity.
Prescribers and pharmacies must enroll in the Caprelsa REMS program by calling (800) 236-9933 or visit www.caprelsarems.com.
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking